Published in
American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 2(66), 2022
DOI: 10.1128/aac.01829-21
Links
Tools
Clinical Relevance of Rifampicin‐Moxifloxacin Interaction in Isoniazid-Resistant/Intolerant Tuberculosis Patients
Journal article published in 2022 by
Vanessa B. Vogensen,
Mathieu S. Bolhuis,
Marieke G. G. Sturkenboom,
Tjip S. van der Werf,
Wiel C. M. de Lange,
Richard M. Anthony,
Dick van Soolingen,
Jan-Willem Alffenaar 
,
Huib A. M. Kerstjens ,
Onno W. Akkerman
,
Huib A. M. Kerstjens ,
Onno W. Akkerman
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Data provided by 
Abstract
Moxifloxacin is an attractive drug for the treatment of isoniazid-resistant rifampicin-susceptible tuberculosis (TB) or drug-susceptible TB complicated by isoniazid intolerance. However, co-administration with rifampicin decreases moxifloxacin exposure.